Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	6.32M 1.93B 5.62M 5.24M 4.78M 9.01M 609M 9.1M 63.52M 24.62M 311M 23.74M 23.23M 998M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	6.32M 1.93B 5.62M 5.24M 4.78M 9.01M 609M 9.1M 63.52M 24.62M 311M 23.74M 23.23M 998M	EV / Sales 2026 *	4.4x	EV / Sales 2027 *	2.43x
Free-Float	72.14%	Yield 2026 *	-	Yield 2027 *	-

09-15	Evogene Ltd. Announces Board Changes	CI
09-11	L.I.A. Pure Capital Intends to Commence a Special Tender Offer to Evogene	CI
09-04	Evogene Ltd. Approves Board Appointments	CI
08-28	L.I.A. Pure Capital Issues Response to Evogene	CI
08-25	Institutional Shareholder Services and Glass Lewis Makes Recommendations to Shareholders	CI
08-18	Evogene Ltd., Q2 2026 Earnings Call, Aug 18, 2026
08-18	Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-17	Freightos Names Yaron Eldad as Chief Financial Officer	MT
07-27	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
07-22	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
07-22	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI

23-10-02	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
23-08-18	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
21-07-29	Evogene : Aegis Capital Starts Evogene at Buy	MT
20-12-01	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

09-30	Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance	PR
08-31	Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward	PR
08-25	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees	PR
08-18	Evogene Reports Second Quarter and First Half 2026 Financial Results	PR
08-18	Evogene : Reports Second Quarter and First Half 2026 Financial Results	PU

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	2004-11-30
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	2021-12-31

Evogene Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news: Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	2010-06-02
Sarit Firon CHM	Chairman	60	2021-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	6.38M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	28.53B
BIONTECH SE	+0.05%	-1.64%	-7.28%	-14.06%	24.34B
Average	-0.25%	-0.59%	+54.39%	+120.28%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+58.77%	+129.91%

	2026 *	2027 *
Net sales	1.44M 438M 1.28M 1.19M 1.08M 2.05M 138M 2.07M 14.42M 5.59M 70.52M 5.39M 5.27M 227M	2.6M 794M 2.31M 2.15M 1.96M 3.7M 250M 3.74M 26.11M 10.12M 128M 9.76M 9.55M 410M
Net income	-12.17M -3.72B -10.82M -10.08M -9.19M -17.34M -1.17B -17.5M -122M -47.36M -598M -45.68M -44.69M -1.92B	-10.2M -3.11B -9.07M -8.45M -7.7M -14.53M -982M -14.67M -102M -39.7M -501M -38.29M -37.46M -1.61B
Net Debt	-	-